While in vivo studies are required to ascertain the safety and the efficacy of targeting HER-3 as an antigen, the combined strategy involving immunotherapy and a broad inhibitor of the HER family seems to be a promising approach to the treatment of HNSCC. The gene discussed is ERBB3; the disease is head and neck squamous cell carcinoma.